Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of NIP292 in Healthy Adults
NCT04720443Phase 1Completed
- Sponsor
- China National Institute of Pharmaceutical R&D
- Start
- Nov 2019
- Primary completion
- Jul 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NIP292 in idiopathic pulmonary fibrosis (IPF), sponsored by China National Institute of Pharmaceutical R&D. Primary endpoints: Incidence, potential significance, and clinical importance of adverse events after single dose at 31 days, Incidence, potential significance, and clinical importance of adverse events after multiple doses at 37 days and 4 more. Started Nov 2019; status: completed.
02
Drugs
NIP292
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT04720443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04720443.